Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2015-08-01
|
| סדרה: | Haematologica |
| גישה מקוונת: | https://haematologica.org/article/view/7463 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|